Michelle Mitchell is a highly experienced chief executive with considerable national and international Trustee and Non Executive experience and leadership experience. She is chief executive at Cancer Research UK.
COVID-19 changed so much of our plans, but it didn’t change everything. In this dark year, there were still pockets of light, writes our CEO Michelle Mitchell.
Last week, the UK Government announced what it would spend money on next year. Overall, the results were a mixed bag – but a step in the right direction, writes Michelle Mitchell.
We’re having to scale down our work to reflect our new situation, but our ambition remains the same, writes our chief executive, Michelle Mitchell.
Because of COVID-19 and the devastating impact it’s had on our income, we could be forced to cut £150 million per year from our research funding.
Without specific and strategic Government support, the COVID-19 pandemic could have a deep and long-lasting effect on our work.
Like so many of us right now, I’ve been thinking hard about how to be a better ally, writes our CEO, Michelle Mitchell.
With a new Prime Minister in office, the Government’s commitments to supporting the NHS and building on the strength of science in the UK must become reality.
‘The word ‘legacy’ is often overused, but not about the late Baroness Tessa Jowell’. Michelle Mitchell reflects on Cancer Research UK’s new brain tumour funding.